Abstract
Giant cell tumor (GCT) is a nonmalignant neoplasm composed of multinucleated giant and mononuclear stromal cells. This study aimed to compare imaging findings of GCT pre- and post-denosumab treatment, including lesion size, percentage of signal intensity/density change, and time of initial objective tumor response. This will have a great impact on selection of most appropriate imaging technique to accurately measure therapy response and its related complications, which would influence the physicians to tailor the treatment regimen to suit each patient. Based on the ICDS criteria, most patients with giant cell tumor of bone show objective tumor response to denosumab.
Keywords: Giant cell tumor, Denosumab, Magnetic resonance imaging, RANKL. GCTB.
References
- Xu S, Adams B, Yu XC, Xu M (2013) Denosumab and giant cell tumour of bone-a review and future management considerations. Curr Oncol.
- Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell- Mazzini J (2019) Denosumab Treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg.
- Qi WX, Tang LN, He AN, Yao Y, Shen Z (2014) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol.
- Sung HW, Kuo DP, Shu WP, Chai YB, Liu CC, Li SM (1982) Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am 64(5):755–761.
- ECR 2014 / C-1095 / Imaging of giant cell tumors of bone. European Congress of Radiology.
- Chawla S, Henshaw R, Seeger L et al (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol.
- Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 25(13):1753–1759.
- Rock MG, Sim FH, Unni KK et al (1986) Secondary malignant giant-cell tumor of bone. Clinicopathological Assessment Of Nineteen Patients. J Bone Joint Surg Am. 68(7):1073–1079.
- Branstetter DG, Nelson SD, Manivel JC et al (2012) Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res.
- Turcotte RE, Wunder JS, Isler MH et al (2002) Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res.
- Mcgrath PJ (1972) Giant-cell tumour of bone: an analysis of fifty-two cases. J Bone Joint Surg Br 54(2):216–229.
- Campanacci M, Baldini N, Boriani S, Sudanese A (1987) Giant-cell tumor of bone. J Bone Joint Surg Am 69(1):106–114.
- Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr (2013) Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics.
- Bertoni F, Bacchini P, Staals EL (2003) Malignancy in giant cell tumor of bone. Cancer. 97(10):2520–2529.
- Ueda T, Morioka H, Nishida Y et al (2015) Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol.
Corresponding Author
Dr Rajendra Chaudhry (MD Medicine)
Professor and H.O.D (Medicine Department), Maharishi Vashishtha Autonomous State Medical College, Basti, UP., India
DOI: https://dx.doi.org/10.18535/jmscr/v9i2.16
